Research programme: viral vaccines - Adamis Pharmaceuticals

Drug Profile

Research programme: viral vaccines - Adamis Pharmaceuticals

Latest Information Update: 09 Jan 2014

Price : $50

At a glance

  • Originator Adamis Pharmaceuticals Corporation
  • Class Cell therapies; Influenza virus vaccines; Viral hepatitis vaccines; Viral vaccines
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Influenza virus infections

Most Recent Events

  • 31 Jul 2013 Suspended - Preclinical for Influenza virus infections in USA (Parenteral)
  • 31 Jul 2009 Preclinical trials in Influenza virus infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top